Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy fo… Read more
Wuhan Hiteck Biological Pharma Co Ltd (300683) - Total Liabilities
Latest total liabilities as of September 2025: CN¥393.09 Million CNY
Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has total liabilities worth CN¥393.09 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Wuhan Hiteck Biological Pharma Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bomesc Offshore Engineering Co
SHG:603727
|
China | CN¥1.27 Billion |
|
Construtora Tenda S.A
SA:TEND3
|
Brazil | R$4.95 Billion |
|
Surfilter Network Technology Co Ltd
SHE:300311
|
China | CN¥560.48 Million |
|
Wilmington plc
PINK:WMGTF
|
USA | $145.71 Million |
|
Fairfax Financial Holdings Ltd Pfd Shs Ser F 5 Yr Rate Reset
PINK:FXFHF
|
USA | $70.70 Billion |
|
Djurslands Bank
CO:DJUR
|
Denmark | Dkr15.06 Billion |
|
Digiworld Corp
VN:DGW
|
Vietnam | ₫7.78 Trillion |
|
Attica Bank S.A.
AT:TATT
|
Greece | €6.29 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Wuhan Hiteck Biological Pharma Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wuhan Hiteck Biological Pharma Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below shows the annual total liabilities of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥525.05 Million | +10.37% |
| 2023-12-31 | CN¥475.73 Million | +28.16% |
| 2022-12-31 | CN¥371.20 Million | +4.72% |
| 2021-12-31 | CN¥354.46 Million | -23.21% |
| 2020-12-31 | CN¥461.62 Million | +12.86% |
| 2019-12-31 | CN¥409.03 Million | -8.24% |
| 2018-12-31 | CN¥445.77 Million | +67.82% |
| 2017-12-31 | CN¥265.62 Million | -20.91% |
| 2016-12-31 | CN¥335.87 Million | +21.81% |
| 2015-12-31 | CN¥275.74 Million | +4.14% |
| 2014-12-31 | CN¥264.78 Million | +42.03% |
| 2013-12-31 | CN¥186.42 Million | -- |